Halozyme Therapeutics reported $786.45M in Loan Capital for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Loan Capital Change
Acadia Pharmaceuticals ACAD:US $ 0M 0M
Agios Pharmaceuticals AGIO:US $ 0M 0.17M
Alnylam Pharmaceuticals ALNY:US $ 433.8M 0.65M
Amarin AMRN:US $ 0M 0M
Amgen AMGN:US $ 33291M 4833M
Aptinyx Inc APTX:US $ 14.04M 14.04M
Arena Pharmaceuticals ARNA:US $ 37.48M 1.3M
Baxter International BAX:US $ 5446M 264M
Cytokinetics CYTK:US $ 124.09M 3.8M
Eli Lilly And LLY:US $ 15522.4M 785.8M
Esperion Therapeutics ESPR:US $ 272.51M 410K
Halozyme Therapeutics HALO:US $ 786.45M 0.88M
Intra Cellular Therapies ITCI:US $ 0M 0M
IONIS PHARMACEUT IONS:US $ 1303M 62.3M
JAZZ PHA JAZZ:US $ 6253.65M 241.68M
Mannkind MNKD:US $ 280.73M 0.47M
Minerva Neurosciences NERV:US $ 0M 0M
Nektar Therapeutics NKTR:US $ 0M 0M
Peregrine Pharmaceuticals PPHM:US $ 138.81M 41.86M
Rigel Pharmaceuticals RIGL:US $ 19.89M 0.03M
United Therapeutics UTHR:US $ 800M 0M